Reactions of Chlorambucil and its main metabolite, Phenylacetic Acid Mustard, with 2’-deoxyribonucleosides and Calf Thymus DNA by Florea-Wang, Diana
TURUN YLIOPISTON JULKAISUJA
ANNALES UNIVERSITATIS TURKUENSIS
SARJA - SER. A I  OSA - TOM. 401




Reactions of Chlorambucil and its main 
metabolite, Phenylacetic Acid Mustard,  
with 2’-deoxyribonucleosides  
and Calf Thymus DNA
by
Diana Florea-Wang
























Painosalama Oy – Turku, Finland 2009
 Abstract 3
AbsTRACT
Chlorambucil is an anticancer agent used in the treatment of a variety of cancers, 
especially in chronic lymphocytic leukemia, and autoimmune diseases. Nevertheless, 
chlorambucil is potentially mutagenic, teratogenic and carcinogenic.
The high antitumor activity and high toxicity of chlorambucil and its main metabolite, 
phenylacetic acid mustard, to normal tissues have been known for a long time. 
Despite this, no detailed chemical data on their reactions with biomolecules in 
aqueous media have been available.  
The aim of the work described in this thesis was to analyze reactions of chlorambucil 
with 2’-deoxyribonucleosides and calf thymus DNA in aqueous buffered solution, 
at physiological pH, and to identify and characterize all adducts by using modern 
analyzing methods. Our research was also focused on the reactions of phenylacetic 
acid mustard with 2’-deoxynucleosides under similar conditions.  
A review of the literature consisting of general background of nucleic acids, alkylating 
agents and ultraviolet spectroscopy used to identify the purine and pyrimidine 
nucleosides, as well as the results from experimental work are presented and 
discussed in this doctoral thesis.
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Structure	 of	 deoxyribonucleic	 acid	 (DNA). DNA is a nucleic acid, a long-chain 
polymer made up of a linear array of monomers called nucleotides.1 Each nucleotide 
is constructed from a heterocyclic nitrogen base, a pentose sugar, and one or more 
phosphate residues. The most common bases are monocyclic pyrimidines and 
bicyclic purines. The DNA contains two purines, adenine (Ade) and guanine (Gua), 













































Chart 1. Structures, numbering of atoms and names of DNA bases.
The structure of the nucleosides consists of the base bonded to carbon-1 of the 
pentose sugar molecule by a N-β-glycosidic bond. The sugar component of DNA is in 
furanose form and it is a β-D-2-deoxyribose. Successive monomer units in nucleic 
acids are connected through a phosphate residue which is attached to the hydroxyl 
on the carbon-5’ of one unit and the hydroxyl on the carbon-3’ of the next unit. 
Thus, the nucleic acids are assembled on a backbone made up of the pentose units 























Chart 2. Phosphate ester backbone: from carbon-5’ of a pentose to the carbon-3’ of the next 
pentose, and further.
The genetic information is encoded in DNA and transmitted from a parent cell to 
its daughter cells through hydrogen-bonding interaction between specific pairs 
of nucleobases, known as Watson-Crick base-pairing. Bases which contain amino 
groups and carboxyl groups are ideal for hydrogen bonding. Every purine base 
forms a stable hydrogen-bonded pair with a specific pyrimidine base: adenine 
forms a base pair through two hydrogen bonds to thymine, while guanine forms a 
base pair through three hydrogen bonds to cytosine (Chart 3). 







































Chart 3.  Watson-Crick base-pairing in DNA.
The three-dimensional model of DNA structure consists of two complementary 
polynucleotide chains held together by hydrogen bonds between the paired bases 
(Figure 1). The two strands are anti-parallel: one strand is arranged 3’  5’ from 
left to right, while the other goes in the opposite direction, 5’  3’ from left to 
right.2,4
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figure 1. DNA double helix model.
Biological	relevance	of	DNA. The biological properties of the DNA are based on 
the precise interstrand hydrogen bonding described above. Deoxyribonucleic acids 
give essential functions in all living organisms, wherein the most vital functions are 
the long-term storage and transmission of genetic information with high fidelity 
from one generation to the next.5,6 
The DNA is exposed to a large variety of harmful physical and chemical agents 
that have a constant damaging effect. There are estimations of 10000 lesions per 
day taking place in human genes in every cell.7 Ultraviolet component of sunlight, 
X-rays, genotoxins present in foods or cigarette smoke, chemotherapeutic agents (i.e. 
alkylating agents), oxygen radicals resulted from the normal cellular metabolism 
may direct to mutations that increase the threat of cancer.8 
1.2.	 Alkylating	agents	and	alkylation	of	purine	and	pyrimidine	
nucleosides 
Alkylation is the transfer of a reactive alkyl group from one molecule to another 
molecule where electron density is high. 
Nucleic acid bases are prone to structural modification by nucleophiles as well as by 
electrophiles and these modifications represent the basis of chemical carcinogenesis. 
In most of the alkylation reactions, the nucleobases play the role of the nucleophile 
that will react with electrophiles, such as alkyl halides (R-X), alkanesulfonates 
(R’-SO2-OR’’) and dialkyl sulfates (R’O-SO2-OR’’) (Scheme 1); in this case, purines 
are alkylated more readily than pyrimidines. Alternatively, pyrimidines may also 
serve as electrophiles when strong nucleophiles, such as hydrazines (H2N-NHR), 





































2-deoxyribose 2-deoxyribose 2-deoxyribose 2-deoxyribose
scheme 2. Reaction of 2’-deoxycytidine with bisulfite ion.9
As discussed above, alkylating agents are reactive electrophiles. They can react with 
the nucleophilic (electron-rich) sites of cellular macromolecules, such as DNA and 
proteins, causing DNA damage by strand breaks, DNA-DNA crosslinks and DNA-
protein crosslinks.11 Alkylating agents are important research topic due to their 
controversy: promising anticancer drugs, but also possible carcinogens, mutagens 
and teratogens. 
1.2.1.	 Classification	of	alkylating	agents	
The classification of alkylating agents is not an easy task due to the many different 
aspects used in classifying them, such as their provenience, number of functional 
groups, mode of action, nucleophilic or electrophilic character/the mechanism of 
their action, chemical and structure similarities.
There are endogenous and environmental alkylating agents, as well as 
alkylating drugs. Endogenous agents are formed during the metabolism. 
S-Adenosylmethionine,12 that is a coenzyme implicated in methyl group transfer in 
biochemical reactions, and nitrosoamines and related compounds are few examples 
of the endogenous alkylating agents. 
Environmental alkylating agents are found in the air, water and foods. Humans 
are most exposed to N-nitroso compounds formed in tobacco smoke. 13 Different 
halocarbons are present in the air in small but detectable concentrations. 
Chloromethane gas is generated by plants, fungi, industrially and it is one of the 
halocarbons present in the highest percentage in the atmosphere.13 Bromo-
compounds (i.e. bromoethane) are more abundant in marine environment. There are 
also different food mutagens, such as aflatoxins, polycyclic aromatic hydrocarbons, 
and heterocyclic amines.14 The oldest anti-cancer drugs are alkylating agents and 
they are still important in the treatment of different types of cancer.15
14 Introduction 
According to the number of the functional groups, alkylating agents are divided into 
three groups: monofunctional alkylating agents, such as methanesulfonates16,17,18 
[i.e. methyl methanesulfonate, MMS (1)] and methylnitrosourea19,20 (2); 
bifunctional alkylating agents, as for example bis(chloroethyl)nitrosourea21,22,23 (3), 
bischloroethyl sulfide24 (4), bis(chloromethyl) ether25 (5), epichlorohydrin26 (6), 
nitrogen mustards; and cyclic alkylating agents, such as 2-chlorooxirane27,28 (7) 
(Chart 4). There are not strict limits between these three categories of alkylating 
agents (see compound 6 that is both, bifunctional and cyclic). However, most of 






































Chart 4. Structural formula of different types of alkylating agents.
Nitrogen mustards, such as 4-[N,N-bis(2-chloroethyl)-p-aminophenyl]butyric 
acid (chlorambucil, CLB, 8), cyclophosphamide29 (9), melphalan30 (10) and 
mechlorethamine (11) (Chart 5), are typical bifunctional alkylating agents and they 
are few of the oldest anticancer agents in clinical use.31 They have the tendency 

























Chart 5. Structures of nitrogen mustards: chlorambucil (8), cyclophosphamide (9), 
melphalan (10) and mechlorethamine (11).
Alkylating agents can be divided also by their mode of action into two categories: 
alkylating agents that react directly with nucleic acids and are known as primary 
carcinogens; and alkylating agents that react after metabolic activation.33 Most of 
the alkylating agents are directly acting carcinogens, such as dimethyl sulfate (DMS, 
12), MMS (1), 2-methylaziridine (13), 1,3-propanesultone (14), epichlorohydrin34 
(6), and old anticancer agents as myleran (15), CLB (8) and cyclophosphamide (9) 

























Chart 6. Structures of directly acting agents.
Quinone methides are known as bioreductive alkylating agents.35,36 A quinine 
methide precursor is activated, forming a very reactive intermediate that can react 
with DNA. The antibiotic mitomycin C37 (16, Scheme 1) is a known example of this 
class due to its high anti-tumor activity; 16 binds covalently to DNA upon reductive 
activation38 and it is the only quinone-containing alkylating agent that was approved 
for general use. 
Scheme 1 shows example of reactions of direct acting alkylating agent, 
triethylenethiophosphoramide,31 and metabolically activated alkylating agent, 

































































scheme 1. Reaction pathways of direct acting and metabolically activated alkylating 
agents.
Dialkylnitrosamines are other examples of alkylating agents that are metabolically 
activated to reactive species.42
Alkylating agents are electrophiles that are able to react at a variety of sites on DNA 
molecules following mainly the rules of electrophilicity and nucleophilicity.33 There are 
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SN1 and SN2 alkylating agents, depending on which mechanism they react with DNA. 
Two basic mechanisms of alkylation are generally accepted: the first-order nucleophilic 
substitution (SN1) and the second-order nucleophilic substitution (SN2). SN1 is referring 
to unimolecular reaction, while SN2 is corresponding to bimolecular reaction. In a 
nucleophilic substitution, an electron-rich attacking nucleophile replaces a leaving 
group from a carbon atom, using its lone pair of electrons to form a new bond to the 

































scheme 2. A representative depiction of the SN1 and SN2 reaction mechanism, in which L is 
the leaving group and Nu is the nucleophile. 
In SN1 substitution reaction, the first step is the formation of an electrophilic planar 
carbocation intermediate; this takes place slowly and it represents the rate-limiting 
step. The covalently bonded adduct is rapidly formed from this intermediate and 
the nucleophile. The stability of the carbocation and/or nature of the leaving group 
determine the reactivity of the electrophile.33 
Strong electrophiles, as for example methyl iodide, dimethylsulfate, are very 
reactive and they react by following the SN2 mechanism. The SN2 reaction involves 
an attack of the electrophilic carbon atom by a nucleophile from the opposite site of 
the leaving group. These types of reactions are dependent on steric accessibility.33 
The electrophiles can be divided into hard electrophiles and soft electrophiles. 
Hard electrophiles that have large dipole moments react at the oxygens of the DNA 
bases, while soft electrophiles that have small dipole moment react at nitrogens 
of the DNA bases. Hard electrophiles, as for example N-methyl-N-nitrosourea, are 
SN1-like alkylating agents, whereas soft electrophiles, as for example DMS, MMS, 
alkyl halides, react preferably with endocyclic sp2-hybridized nitrogen atoms of 
nucleosides43 in a SN2-like fashion. 
Platinum compounds are also an important class of chemotherapeutic alkylating 
agents. Cisplatin (17) and carboplatin (18) are few examples of these types of 
compounds (Chart 7). They are neutral complexes that move freely into the cells until 
their two chlorides are exchange by water and form bi-positive charged molecules 
















Chart 7. Chemical structures of platinum compounds.
Cyclopropylpyrroleindoles derivatives, such as duocarmycin A44 (19), are a class 
of alkylating agents and antitumor antibiotics that exhibit their biological effects 
through a reversible, sequence-selective minor groove alkylation of DNA.45,46 The 
reversibility of drug – DNA adducts might be the main reason for which these 
antitumor alkylation agents act selectively on the tumor cells. Scheme 3 shows the 












































scheme 3. Reversible DNA alkylation reaction of duocarmycin A.
1.2.2.	 DNA	crosslink
The antitumor activity of bifunctional alkylating agents is associated to their 
capability to induce DNA-DNA crosslinks within the DNA duplex.49 Bifunctional 
alkylating agents can also react with the nucleophilic sites within proteins, giving 
rise to DNA-protein crosslinks. 50 These crosslinks are also responsible for the large 
cytotoxic potential of the alkylating agents.51,52
The alkylation reaction on DNA generates different types of products: monoalkylated 
adducts and crosslinks, which can be intrastrand crosslinks and interstrand 
crosslinks (Figure 2). 
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figure 2 . Type of products in DNA alkylation.15
The interstrand crosslink arises from the covalent binding of the alkylating agent 
to both strands of the double helix (Scheme 4) and it is considered to be the most 
toxic lesion.53 In order to form DNA crosslink, alkylating agents have to contain two 
or more reactive sites (to be multifunctional) and two reactive nucleophilic sites of 
DNA must be present in close proximity. Monoalkylated adducts and intrastrand 
crosslinked products may be formed when the alkylating agent is smaller than the 
width of the minor groove of the DNA strand, while the interstrand product may 
be formed when the alkylating agent is longer than the width of the minor groove 
of the DNA strand. Monoalkylated adducts appear when an alkylating agent that 
already has reacted with DNA additionally reacts with an external nucleophile, such 
as water or a buffer component. Thus, the type of product that is formed depends on 
the nucleophiles present in the system as well as on the structure of the alkylating 
































scheme 4. Example of DNA interstrand crosslink formation in the case of 
mechloroethamine.54,55 Chloride is the leaving group and DNA holds the nucleophilic site.
The DNA interstrand cross-linking may disrupt crucial cellular processes including 





Alkylating agents can react at any of the nucleophilic sites (endocyclic and exocyclic 
nitrogens, exocyclic oxygens) of the purine and pyrimidine bases of nucleic acids in 
aqueous solution at neutral pH56,57 (Chart 8). Furthermore, the oxygen atoms of the 
phosphate internucleotide linkages are prone to alkylation.58 However, there are 
two exceptions: the nitrogen in position 9 of the purines and the nitrogen atom in 






























































Chart 8. Alkylation sites of the nucleic acid bases and the main type of substitution at each 
nucleophilic site.
It is generally known that the base-paired positions of nucleic acids are shielded 
from modifications.59 This is basically the case with the nitrogen atoms but not with 
the oxygens.60 Base-paired oxygens, such as O2 of Cyt, O6 of Gua, O4 of Thy, possess 
an extra pair of electrons that is free to react even in dsDNA.61,60
In the case of cytidine, O2-alkylation was considered to be impossible due to the 
instability of the resulting adduct.62 In 1976, Singer62 reported for the first time the 
O2-alkylcytidine derivatives that were obtained as major products in the reaction 
of cytidine with N-methyl-N-nitrosourea and N-ethyl-N-nitrosourea at neutral 
pH, in aqueous media. It was also observed that weaker carcinogens, such as 
dimethylsulfate, do not alkylate O2 position of cytidine.
A very important factor in determining the site of alkylation is the nature of the 
alkylating group (i.e. ethyl vs. methyl).10 The N7 of guanine base is the principal site 
of alkylation of nucleic acids bases with alkylating agents.10 
1.2.4.	 Basics	of	carcinogenesis	and	introduction	to	alkylating	agents	as	
carcinogens
Based on extensive empirical observations,63 as well as on mathematical model,64 
human carcinogenesis is a multistep process in which three phases, initiation, 
promotion and progression, follow each other in a sequential manner. The nature 
of these stages is very complex and they are described in a simplistic mode in the 
following text. However, we have to bear in mind that carcinogenesis is far from 
a simple process, but it consists of multiple genetic alterations of cells, involves 
multiple steps, and is affected by multiple environmental factors.65 
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There are many different endogenous and exogenous carcinogenic factors to which 
humans are exposed: chemicals, physical agents, radiation, viruses and bacteria.66 
The identification of carcinogens is a complicate process that involves the scientific 
evaluation of human epidemiological studies, animal bioassays, and mechanistic 
and other relevant data. 67 According to the IARC Monographs, there are more than 
400 agents classified as carcinogenic to humans, probably carcinogenic to humans 
or possibly carcinogenic to humans.68
The exposure to mutagens is followed by the initiation step which starts with the 
alterations of DNA due to spontaneous or carcinogen-induced genetic changes, 
epigenetic modifications, or inherent genetic mutations.66 The alterations in specific 
genes will cause the change in the initiated cell’s response to its microenvironment, 
giving a possible growth advantage compared to normal cells.69 In initiation 
phase, the genetic cellular modifications take place very slowly and with small 
or unobservable changes in the cellular or tissue morphology. In this stage, a 
permanent inclination to develop cancer exists and it increases by time, and further 
tumor will develop only if the environmental conditions changes in such a way that 
further evolution of tumor is favored.
The initiation is followed by the promotion stage in which a clonal expansion of 
initiated cells takes place. The formation of tumor is stimulated by a non-mutagenic 
external factor, as for example wounding or inflammation.70 A non-malignant 
tumor is formed and, without additional stimulus, the tumor may regress.64 This 
step is associated with hyperproliferation, apoptosis, tissue remodeling and 
inflammation.71
In the progression phase, the tumor goes through a malignant transformation 
with unlimited and invasive growth. Progression does not involve external 
stimulus usually. This stage is associated with alterations in gene expression and 
supplementary genetic damage because of progressive genomic instability.72
Carcinogens can be classified into directly acting agents and metabolically 
activated agents. The direct carcinogens are reacting with nucleic acids without 
enzymatic activation, while the metabolic activated carcinogens, known also as 
procarcinogens, require metabolic activation. The last DNA-reactive carcinogenic 
species of procarcinogens are electophilic and this is a general characteristic 
of all procarcinogens’ metabolic activation.73 Additionally, the damage of DNA 
can be caused by many directly acting carcinogens through their electrophilic 
intermediates.74
A further classification will divide the directly acting compounds into nonalkylating 
and alkylating agents. Nonalkylating agents change base pairing by deamination 
or a shift in tautomeric equilibria, while the alkylating agents substitute a proton 
with an alkyl moiety. Alkylating agents, including melphalan, chlorambucil, 
chlornaphazine, mustard gas, muleran and cyclophosphamide, are few of the known 
human carcinogens.75,76
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Alkylating agents are used widely in cancer chemotherapy. However, they may 
damage the DNA and be mutagenic and carcinogenic. They are known to alkylate 
DNA at various sites on bases, sugars and phosphate groups. The O6 position 
of guanine is the major mutagenic and lethal lesion among all the alkylation 
sites; the O6-alkylguanine is predominantly repaired by O6-alkylguanine-DNA 
alkyltransferase. 77
1.2.5.	 Stability	of	alkylated	DNA	adducts
Under physiological conditions, many alkylating agents bind to various heteroatoms, 
such as nitrogens and oxygens, of genomic DNA.33 The DNA adducts are formed by 
the covalent binding of alkyl groups to nucleophilic sites on DNA and they show 
different levels of stability. On one hand, for example, 3-alkylpurine nucleosides 
and 7-alkylpurine nucleosides are easily depurinated at neutral pH because of 
the lability of their glycosidic bond. On other hand, same and other adducts can 
also be removed enzymatically by different pathways: by glycosylase mediated 
excision repair or by transferase enzymes specific for the removal of only the alkyl 
group.58,78,79 
It was observed that only a small percentage of adducts are stable and stay bound 
to DNA for a long time33 and also that adducts formed in vitro are usually more 
stable than adducts formed in vivo.78 
1.2.6.	 DNA-alkylation	repair	processes
It is generally believed that the alkylating agents/drugs bind covalently to DNA and 
lead to misreading of the DNA code, cross-linking of DNA,80 and single-stranded and 
double-stranded breaks of DNA.81 Most of the modifications of nucleic acid bases 
can be repaired in vivo by repair enzymes, but not all, and cell may die without a 
proper repair of the lesion.82  
In living cells, there are two types of basic repair processes of lesions/damages 
induced by DNA alkylation. The first process consists of the direct base repair in 
which the modifying alkyl group is transferred directly to the repair protein. For 
example the O6-methylguanine-DNA methyltransferases and 3-methyladenine-DNA 
glycosylases protect the cells from the killing effect of alkylating agents.80 In the 
second type of repair, the modified base is removed by a glycosylase; an apurinic or 
apyrimidinic site is formed and this will be repaired by an excision-repair process.33 
There is base excision repair and, in some extend, the nucleotide excision repair 
(NER). Bifunctional alkylating agents, known anti-cancer drugs, cause complex 
DNA lesions that involve complex repair mechanism that depends on the type of 
lesion.7,13 For example, NER is repairing the DNA damages caused by UV light, while 
base excision repair finds minor damages that take place at nucleobases and sugar 
moieties.7 However, other repair systems do exist.
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1.2.7.	 Biological	activity	of	DNA-alkylation	adducts
Since O6 site of guanine was suggested to be important for mutation induction,83 
many scientific groups started to analyze the biological activity of DNA-adducts. 
It is considered that O-alkylations, such as O6-alkylG and O4-alkylT, are highly 
mutagenic and genotoxic.84 O6-Alkylguanine and O4-alkylthymidine are of great 
biological importance85,86 and show promutagenic potential in both RNA and DNA 
in vitro assays58 and they were found also in vivo.87,88 O6-AlkylG pairs with thymine 
producing G  A transitions, while O4-alkylT pairs with guanine producing T  
A transitions.57 The alkylation of the O2 position of all deoxypyrimidines causes a 
high destabilization of the glycosidic bond;89 these adducts are much more labile 
than their parent compounds. 
In the case of DNA methylation, probably the most significant products are O6-
methylguanine and 3-methyladenine. The first is a miscoding base and the second 
is a cell-killing lesion.90 N-alkylations, as for example 1-alkylA and 3-alkylA, 
are less mutagenic, but they are cytotoxic.91 In general, 1-alkylpurines and 
3-alkylpyrimidines were found to inhibit DNA synthesis and to contribute to 
cytotoxicity.58 
7-AlkylG is the most observed lesion in DNA and RNA and itself is not harmful. 
The situation changes when 7-alkylG goes through spontaneous depurination and 
enzymatic removal, giving arise to cytotoxic abasic sites.13
SN1 alkylating agents are highly mutagenic due to their ability to react with the DNA 
sites containing oxygens and therefore causing the formation of mispairing adduct, 
especially O6-alkylguanine and O4-alkylthymine.92
1.3.	 Ultraviolet	spectroscopy	used	in	characterization	of	purine	and	
pyrimidine	nucleoside	adducts
There are several types of molecular excitations, but four of them are especially 
important to chemists because they give information related to the molecular 
structure of a particular compound. These are the absorption of infrared radiation 
(IR), which tells about the type of functional group that is present in the molecules, 
the absorption of ultraviolet and visible light (UV), which proves the compounds 
that contain π bonds, nuclear magnetic resonance (NMR), which gives information 
about the carbon skeletons of molecules and the number of hydrogen atoms present 
on each carbon atom, and mass spectrometry (MS), which elucidates the elemental 
composition and the structure of a molecule. UV spectroscopy is especially useful 
in determining the site of base modifications because of the extensive literature 
data available that can be used as a reference material. In addition, the method is 
experimentally very easy.
Molecular absorption in the ultraviolet region of the spectrum depends on the 
electronic transitions of the molecule. 93,94,95,96,97 Most UV absorptions by organic 
molecules are attributed to transitions involving the excitation of an electron from 
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the highest occupied molecular orbital to the next higher energy orbital, the lowest 
unoccupied orbital.
Absorption	 spectra	 of	 nucleosides	 and	 their	 derivatives.	 It is known that the 
sugar and phosphate components of nucleotides do not have any significant UV 
absorption above 230 nm, which means that the nucleotides and nucleosides have 
UV spectra alike to those of their constituent bases.98 Nucleic acid bases and their 
derivatives show a strong UV absorption in the range from 240 to 300 nm, 99 which 
greatly facilitates the detection and quantification of nucleosides. 
In nucleic acid studies, three different parameters of absorption spectroscopy 
may be utilized: molar absorptivity, wavelength of maximum absorption, and 
hypochromicity.96 The absorption maximum is close to 260 nm 100 and the molar 
absorptivity to 104 M-1cm-1. Hypochromic effect appears when a nucleic acid base is 
inserted into a polymeric structure and its absorptivity is reduced. 
Nucleosides have pKa-values in the normal pH-range from 0 to 14 (Ado at 3.7, Guo 
at 2.0 and 9.5, Ctd at 4.3, and Thd at 9.7) and the wavelengths of the absorption 
maxima (λmax) and the respective molar absorptivities (ε-values) are changed on 
passing these pH values. 99 However, at pH 7 all nucleosides are neutral. 
UV	 spectroscopy	 used	 in	 the	 characterization	 of	 adducts. UV spectroscopy 
is a useful tool for detection of base modifications and characterization of the 
adducts that are formed. Characterization of the adducts is usually verified by 
other spectroscopic techniques, such as mass spectroscopy and nuclear magnetic 
resonance spectroscopy.
Figure 3 includes examples of UV spectra of nucleosides and their modified 
counterparts. Usually, knowing the value of maximum absorption (λmax) of a 
compound, it is easy to observe if a modification took place on that compound by 
checking the λmax of the new formed products. If the value is different, an adduct has 
been formed. Sometimes also the shape of the spectra may indicate the presence of 
the modification. 
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figure 3. Neutral UV spectra of (A) adenosine (λmax = 259, —) and N6-ethyladenosine (λmax 
= 268, …), (b) guanosine (λmax = 253, —) and N6-ethylguanosine (λmax = 248, 280 …), (C) 
cytidine (λmax = 271, —) and N3-ethylcytidine (λmax = 279, …), and (D) thymidine (λmax = 
267, —) and O4-ethylthymidine (λmax = 279, …) recorded in H2O. Spectra adapted from Ref. 101.
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2. AiMs Of The Thesis
Chlorambucil (CLB) is an aromatic nitrogen mustard and an alkylating agent 
originally synthesized by Everett et al. in 1953.102 It has been mainly used in the 
chemotherapy of chronic lymphocytic leukemia.103,104,82,105 Other clinical applications 
include Hodgkin’s lymphoma, non-Hodgking’s lymphoma,106 Waldenström’s 
macroglobulineamia,107 trophoblastic neoplasms,108 polycythemia vera,109 ovarian 
carcinoma,110 breast cancer and some other tumors. It can also be used as an 
immunosuppressive drug for autoimmune and inflammatory conditions, as for 
example nephrotic syndrome.111
Like other alkylating agents, CLB binds covalently to DNA,112 RNA and proteins. 
The covalent binding of CLB to DNA may cause misreading of the DNA code, cross-
linking of DNA, single-stranded and double-stranded breaks of DNA,81 and death 
of the cell.82 It is known that therapeutic alkylating agents, including CLB, may 
generate second tumors in patients who have taken these drugs as a treatment for 
their primary cancer.113 CLB, although used extensively in cancer chemotherapy, 
is itself potentially mutagenic,114,115 teratogenic,116 and carcinogenic, 54,77 and an 
increased incidence of acute leukemias and other secondary malignancies has been 
reported in patients who have received this drug.117 However, exhaustive chemical 
data on CLB reactions with biomolecules in aqueous solution have not existed. 
The main aim of the thesis was to identify, characterize and quantify adducts 
formed in the reactions of chlorambucil with calf thymus DNA in aqueous 
solution at physiological pH. Therefore, for an easier understanding, the reactions 
of chlorambucil with nucleosides were followed, alkylation products were 
characterized and quantified and the results were used further as references 
for the reaction of chlorambucil with single- and double-stranded DNA. Also the 
reactions of phenylacetic acid mustard (PAM), chlorambucil’s main metabolite, 
with nucleosides were studied.
The goals were achieved by detailed study on the reactions of chlorambucil with 
nucleosides118,119 and single-stranded and double-stranded DNA,120 and the reaction 
of phenylacetic acid mustard with nucleosides.121 Adducts were isolated and 
purified by chromatography; then they were characterized by chromatographic, 
spectroscopic and spectrometric methods. The identification of the products formed 
in DNA treated with chlorambucil is essential to be able to understand better the 
properties of chlorambucil as a human carcinogen, the molecular mechanism of its 
antitumor effect and to make a better use of it in clinical chemotherapy.
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3. ResulTs AND DisCussiON 
This section deals with general knowledge related to chlorambucil and 
phenylacetic acid mustard and with the results obtained and described in the 
original publications.118,119,120,121 CLB and PAM behave similarly in their reactions 
with nucleosides and give same type of products. Therefore, the reactions 
of CLB at physiological pH were studied in the presence and absence of 
2’-deoxyribonucleosides and used as examples, being mainly described in the 
following text; exception makes the case of dGuo, in which its reaction with PAM 
will be described. 
3.1.	 Chlorambucil	versus	phenylacetic	acid		mustard	
CLB is an orally administrated drug that is in clinical use for several decades and yet 
its optimal use is not established.122 CLB is a drug used often as a reference when 
new chemotherapeutical drugs, especially purine analogues as fludarabine,123,124 
cladribine125,126 and pentostatin,127,128 are developed and tested clinically. CLB 
can be purchased from different chemical suppliers. Phenylacetic acid mustard 
is the metabolite of CLB and it was synthesized by different methods for many 
years;102,129,130 PAM is not commercially available. 
Chlorambucil undergoes fast gastrointestinal absorption and it is nearly entirely 
metabolized. CLB is metabolized mainly by β-oxidation of the butyric acid side 
chain131 to {4-[bis(2-chloroethyl)amino]phenyl}acetic acid (PAM, 21) through 
the intermediate (E)-4-{4-[bis(2-chloroethyl)amino]phenyl}but-3-enoic acid 























scheme 5. Metabolism of chlorambucil 
As other aromatic and aliphatic nitrogen mustards, CLB and PAM decompose 
in aqueous media and form covalent bonds with a variety of nucleophiles. The 
mechanism of decomposition of CLB and PAM is described in Scheme 6 and 
it consists of an intramolecular, rate-determining attack of an unprotonated 
N-atom to form an aziridinium ion intermediate, followed by attack of an external 
nucleophile.135,136,137,138,139 






























scheme 6. Mechanism of decomposition of CLB and PAM  
The rate-limiting step (Scheme 6) shows that the reactivity of CLB/PAM is not 
influenced by the external nucleophiles, but by the internal nucleophile which is 
the nitrogen atom. The external nucleophile then traps the cyclic aziridinium ion 
intermediate obtained.
It was observed that the rate of decomposition of CLB and PAM is significantly 
slower in the presence of chloride ion in the solution, 131,140 which is in accordance 
to the behavior of other aromatic nitrogen mustards.137,139,141 Thus, chloride ion has 
a stabilizing effect on CLB/PAM. An obvious stabilizing effect on CLB is encountered 
in the case of high concentration of H+ (lower pH) and chloride in human gastric 
juice.131 
Effects of the fluid matrices on the decomposition of CLB and PAM, as well as the 
cellular incorporation and protein binding of the drug were studied in vitro.131,140  In 
the absence of nucleophiles (i.e. unbuffered water, cacodylic acid buffer and perchloric 
acid solution), the main reaction is CLB/PAM hydrolysis yielding monohydroxy 
derivative as an intermediate and dihydroxy derivative as the stable end product. In 
the presence of nucleophiles (i.e. phosphate-buffered solution, formic acid and acetic 
acid buffers), extra products are formed from the ions (i.e. phosphate, or acetate, or 
formate) present in the reaction mixtures with the aziridinium ions derived from 
CLB/PAM. 
It is known that approximately 99 % of CLB binds immediately to plasma protein.142 
Albumin is the main plasma protein that participates in this binding in human 
blood.143 CLB binds non-covalently to the hydrophobic pockets of albumin, which 
explains the decrease of decomposition (hydrolysis) of the drug in plasma and the 
considerable stabilization effect on the drug. The decrease in the decomposition of 
CLB due to the binding to albumin is proven also by the fact that the aziridinium 
ion formation is not favorable in hydrophobic surroundings and that the cellular 
incorporation of CLB increases when the concentration of plasma protein 
decreases.140 
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CLB and PAM have positive effect, as killing the tumor cells, and negative effects, as 
being mutagenic, teratogenic and carcinogenic. However, the manner of their action 
is unclear.80 
It was revealed that the pharmacological activity of CLB, its analogs and metabolites 
depends of a variety of facts and some controversy is present.134 Some studies 
show approximately twice stronger acute toxicity of PAM compared to CLB in 
mice.132,134,144,145  More disputed is the antitumor activity of PAM that is similar to 
CLB132 or two-fold higher than CLB.134,144 In addition, PAM has similar cytotoxic 
activity as CLB against the human tumor cells in vitro,146 but higher teratogenic 
and cytotoxic effect in a rat-embryo model.147 However, the therapeutic index of 
the metabolite is similar134 to or two-fold lower132 than the therapeutic index of the 
parent drug. A reason for the lower therapeutic index may be the type of metabolism 
involved.148  The bifunctional alkylators, including CLB and PAM, are known to exert 
their cytotoxic action through the DNA-cross linking.149 
CLB and PAM are SN2 type of alkylators, which means that they react mainly with 
the endocyclic nitrogens of the purine and pyrimidine nucleosides. The half life of 
PAM in aqueous solution at neutral pH is slightly shorter than the one of CLB140, 150 
and suggests that PAM is slightly more reactive compared to CLB. 
Based on their chemical structure, PAM is slightly more soluble in water than CLB.
3.2.	 Reactions	of	chlorambucil	and	phenylacetic	acid	mustard	in	the	
absence	of	2’-deoxyribonucleosides	
Since the predominant reaction of CLB and PAM in aqueous solution is their 
hydrolysis, the identification of the major products of hydrolysis was necessary 
prior to studies on the reactions of CLB and PAM with 2’-deoxyribonucleosides.
CLB and PAM were allowed to react in a nonnucleophilic buffer (cacodylic acid, 
50 % base) at pH 6.8 and 37  ̊C for 24 hours and the reactions were followed by 
HPLC techniques. The products of CLB and PAM hydrolysis, respectively, were 
characterized by HPLC-MS as well as by spiking with authentic samples synthesized 
according to the literature.140,151 
Products of CLB and PAM hydrolysis are shown in Chart 9. In the case of CLB, the 
major product was N,N-bis(2-hydroxyethyl)-p-aminophenyl butyric acid (23) with 
a molecular ion of 268. The second most abundant hydrolysis product was an ester 
(25) with a molecular ion of 517. Other products formed were esters 26 and 27 
with a molecular ion of 780, and an ether derivative 24 with a molecular ion of 517; 
24 was stable under basic conditions, which proved this structure to consist of an 
ether bond. The structures of 25-27, containing an ester linkage, were confirmed 
by saponification: all of them formed compound 23.


















































where n=1 for PAM
n=3 for CLB
Chart 9. Main products of the hydrolysis of CLB and PAM
The pseudo-first-order rate constants were determined based on the hydrolysis 
of CLB and PAM at physiological conditions. The rate of decomposition of the two 
mustards were similar, as the kobs for the disappearance of CLB and PAM were 
5.84×10-4 s-1 and 4,44×10-4 s-1, respectively. The effect of an external nucleophile, 
imidazole, on the product distribution was also studied. The results are incorporated 
in Table 1.
Table 1. Pseudo first-order rate constants (kobs) of hydrolysis and mole fraction (χ) of 
the diols of CLB and PAM as the function of [imidazole]; where diols refer to 4-(4-(bis(2-
hydroxyethyl)amino)phenyl)butanoic acid and 2-(4-(bis(2-hydroxyethyl)amino)phenyl)





presence of 0.05 M 
imidazole
	χ	[%]	of	diol	in	the	
presence of 0.10 M 
imidazole
Clb 5.86 ± 0.11 0.51 0.21
PAM 4.44 ± 0.03 0.52 0.21
3.3.	 Reactions	of	chlorambucil	and	phenylacetic	acid	mustard	with	
2’-deoxyribonucleosides	
2.5 mM CLB (8) and PAM (21), respectively, were allowed to react in the presence 
of 16.1 mM 2’-deoxynucleosides in 0.2 M cacodylic acid buffer (50 % base, pH 
6.8) for 24 hours at 37  ̊C. However, the concentration of CLB in the reaction with 
2’-deoxyadenosine (dAdo) was 0.6 mM. The nucleosides used in these studies 
were dAdo, 2’-deoxyguanosine (dGuo), 2’-deoxycytidine (dCtd), 2’-deoxy-5-
methylcytidine (dMeCtd), and thymidine (Thd). CLB and PAM reacted with various 
heteroatoms of the nucleosides and numerous adducts were obtained, although the 
main reaction observed was the hydrolysis of CLB and PAM. 
The reactions were followed by HPLC techniques. After the reactions were 
completed, the reaction mixtures were injected directly onto the column and 
analyzed by analytical HPLC. Then the products from the reaction mixtures were 
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separated by semipreparative HPLC and the obtained fractions were collected and 
characterized by means of UV, HPLC-MS, ESI-MS and NMR.
3.3.1. Reactions of chlorambucil and phenylacetic acid mustard with 
2’-deoxyadenosine
The HPLC trace on the reaction of CLB with dAdo after 24 hours is shown in Figure 
4. The substances marked as 28-34 are CLB - dAdo adducts, compounds 23 and 
25 are products of CLB hydrolysis, while the peaks marked with asterisks are 
unidentified impurities. 
figure 4. HPLC trace of the reaction of 0.6 mM CLB with 16 mM dAdo in 0.2 M cacodylic acid 
buffer (50 % base) after 24 hours at 37  ̊C.
Adducts 28 and 32 (Chart 10) gave the same molecular ion of 501 that referred to 
the structures were the alkylation had taken place at one site of dAdo. The presence 
of the fragment ion 385.3 in both adducts indicated the loss of the carbohydrate 
moiety and proved that the site of alkylation was at the adenine moiety. Several 
facts were taken into account to clarify whether the alkylation had occurred at 
the endocyclic or exocyclic nitrogen atom (N1 or N6, respectively) of dAdo: a) the 
intensity of 385.3 ion was larger in the MS spectrum of 32 than in the spectrum of 
28; b) in the ultraviolet absorption spectra, the maximum absorption of the 28 is 
red-shifted comparing to 32 at neutral pH (Figure 5), which means that λmax value of 
28 is lower than of 32; this is in accordance with previous literatures related to the 
UV spectral properties152, 101 for endocyclic and exocyclic N-atoms, respectively. 























where n=1 for PAM
n=3 for CLB
Chart 10. Structures of N1- and N6-alkylated adduct of CLB/PAM – dAdo reactions. 
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figure 5. UV spectra of substance 28 marked with dashed line and substance 32 marked 
with solid line.
The site of alkylation of compounds 28 and 32 was verified by comparison to 
the available literature data on 1H NMR.153 The resonance of the adenine-linked 
methylene protons is different when the alkylation is on endocyclic nitrogen or 
exocyclic nitrogen of adenine. In the case of CLB, the chemical shift of the proton 
from Ade-CH2 was shifted from 4.42 ppm for N1-alkylated adduct to 3.80 ppm for 
N6-alkylated derivative.
Based on the facts described above, 28 was assigned as an N1-adduct and 32 as an 
N6-adduct of dAdo. Substance 28 can be also assigned as N1-alkylated product based 
on the Dimroth rearrangement154,155,156 of 28 to 32 when treated with aqueous base, 
reaction that is characteristic for N1-alkyladenine nucleosides. This transformation 
is a base-catalyzed reaction.
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It is known that different alkylating agents alkylate adenosine at N1 and N6 site.157 
N6 adduct of the reaction of CLB with dAdo was the result of the direct alkylation 
of N6 site of the nucleoside, and not a result of the Dimroth rearrangement of the 
N1 adduct; that was demonstrated by the very slow rearrangement of N1 to N6 
derivative under the reaction conditions employed. 
Compound 31 (Chart 11) had the same molecular ion of 501, as 28 and 32, in the 
case of reaction of dAdo with CLB. This adduct was identified as a carbohydrate 
derivative based on its mass spectra that shows a fragment ion of 366, which 
represents the loss of adenine base. A similar spectrum was observed previously150 
for an adduct of 2’-deoxyguanosine in which the alkylation had taken place at the 
2’-deoxyriboside moiety. Because of steric reasons, substance 31 was tentatively 












where n=1 for PAM
n=3 for CLB
Chart 11. Structures of 5’-O-alkylated adduct of CLB/PAM – dAdo reactions.
Adducts 29 and 30 (Chart 12) had the same molecular ion mass that referred to an 
adduct where the alkylation had taken place at only one site of the adenine base. 
In the case of CLB – dAdo reactions, the MH+ was 385 for compounds 29 and 30. 
This information and the fact that the alkylation at N3 or N7 of 2’-deoxyadenosine 
labilizes the N-glycosidic bond81, 101, 158  led us to the believe that 29 and 30 were N3- 

















where n=1 for PAM
n=3 for CLB
Chart 12. Structures of N3- and N7-alkylated adduct of CLB/PAM – dAdo reactions 
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The final assignment was based on NMR experiments (1H- and 13C-NMR, COSY, 
NOESY, HSQC, HMBC) which were carried out to assign unequivocally the site of 
alkylation within these two adducts. Spectra were recorded in D2O or DMSO-d6 at 
25  ̊C. Figure 6 shows the 1H NMR spectra of 29 and 30 in DMSO-d6. According to 
literature, 159,160 the Δδ of the chemical shifts of the H-2 and H-8 protons is larger 
with 3-alkyladenine than with the corresponding 7-alkyladenine.  In the current 
case, Δδ of 29 was 0.36 ppm and Δδ of 30 0.13 ppm. The carbon chemical shifts 
in the 13C NMR spectra for 29 and 30 also showed clear differences between the 
alkylation at N3 or N7 of adenine.
figure 6. 1H NMR of N3-alkylated adenine (up) and N7-alkylated adenine (down); run in 
DMSO-d6 at 25  ̊C.
While the 1H- and 13C-NMR experiments together provided substantial evidence 
for structural characterization of the N3- and N7-adducts, the NOE correlation 
brought the most conclusive information for the identification of the alkylation site. 
It was crucial that the NOESY experiment was done in DMSO-d6, so that the NH2-
protons and the correlation with them could be observed. Substance 30 showed 
correlation between the protons of NH2 of adenine and the protons of Ade-CH2 due 
to their vicinity in space (Figure 7) and it was assigned as N7-alkylated adduct, 
while substance 29 did not present this type of correlation and it was assigned as 
the N3-alkylated adduct.  
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figure 7. The significant NOE correlation in N7-alkylated adenine (30).
There are many reactive chlorambucil dimers, such as monochloro, dichloro and 
trichloro derivatives of 25, in the reaction mixtures and this could be an explanation 
for the appearance of esters in the reaction mixture. Substances 33 and 34 (Chart 
13) were tentatively assigned as the esters of N1 adduct of 2’-deoxyadenosine based 
on their mass spectra and their lability under basic conditions due to hydrolysis of 

































where n=1 for PAM
n=3 for CLB
Chart 13. Structures of N1-adducts derived from the reaction of CLB dimers/PAM dimers 
with N1-adduct of dAdo. 
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Cross-links, in which one chlorambucil molecule bridged two dAdo molecules, were 
not observed.
One extra minor adduct was produced by the reactions of PAM and CLB with dAdo. 
Its proposed structure is shown in Chart 14 and, based on the isotopic distribution 
observed in MS data, it might be N1-alkylated adduct of dAdo that still has a chlorine 
atom attached to ethyl chain of the molecule. It is not known why the second chlorine 












where n=1 for PAM
n=3 for CLB
Chart 14. Structure of N1-adduct with a Cl-atom left present in PAM-dAdo reaction.  
Hence, many adducts were detected and, as expected,31 the N1-alkylated derivative 
was the main adduct among them. Other alkylation sites observed in the reaction of 
CLB/PAM with dAdo were N6, N7, N3 and 5’-O. 
3.3.2. Reactions of chlorambucil and phenylacetic acid mustard with 
2’-deoxyguanosine
The reaction of CLB with dGuo had been in the attention of our laboratories before.150 
In this thesis work, the reaction of phenylacetic acid with 2’-deoxyguanosine was 
studied and the products characterization was based on the previous literature.150 
The HPLC trace for the reaction of PAM with dGuo after 24 hours is shown in Figure 
8. Several adducts (35-45) were identified and characterized by means of HPLC-MS 
and 1H NMR.
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figure 8. HPLC trace of the reaction of 2.5 mM PAM with 16.1 mM dGuo in 0.2 M cacodylic 
acid buffer (50 % base) after 24 hours at 37   ̊C. Note: 23, 25 are products of PAM hydrolysis 
and peaks marked with * are impurities.
The most abundant adduct formed was 35 (Chart 15). Its structure was analyzed by 
MS which showed the molecular ion 373 and a fragment ion 222 that corresponds 
to the mass of the CME substituent (Chart 15). The presence of ion 222 indicates 
the alkylation on guanine base. 1H NMR analyses proved that 35 is the N7-adduct 
of guanine. This is as expected31 because the N7 site is the most nucleophilic site of 









35 where n=1 for PAMn=3 for CLB
CME is 2-((4-(carboxymethyl)phenyl)(2-hydroxyethyl)amino)-
ethyl substituen, when n=1
CPE is 2-((4-(3-carboxypropyl)phenyl)(2-hydroxyethyl)amino)-
ethyl substituent, when n=3  
Chart 15. MS spectra and structure of N7-alkylated guanine from the reaction of PAM with 
dGuo.
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The second most abundant adduct was 36 that had a molecular ion of 506 (Chart 















36where n=1 for PAM
n=3 for CLB
Chart 16. MS spectra and structure of N7,N7-bis alkylated guanine from the reaction of PAM 
with dGuo.
Four products (37-40) had the same molecular ion of 489 (Chart 17). They were 
tentatively identified according to their MS data (Figure 9 a-d). Compound 37 had a 
fragment ion of 338 that indicated the loss of unmodified guanine base. This means 
that the reaction with the alkylating agent had taken place at the carbohydrate 
moiety, most likely at 5’-O. Substance 37 was identified as the 5’-O-alkylated 
adduct.
Fragment ion 373 is present in the mass spectra of compounds 38, 39 and 40, 
indicating the loss of the sugar moiety, and that the alkylation had taken place 
at the guanine base. Thus, the alkylation site could to be N1, N2, N3 or O6 site of 
guanine base. Compounds 39 and 40 had a fragment ion 222 indicating the 
cleavage of the CME group. Based on our observations, the absence of that fragment 
was characteristic to the compounds were the alkylation had taken place at their 
endocyclic N atom, while its presence was an indication that the alkylation had 
taken place at one of the exocyclic heteroatoms of the guanine base. In the case 
of 39, the intensity of the signal at 222 was much higher than with 40 and, on the 
basis of the previous studies of CLB with dGuo,150 that could be characteristic to 
the O6-alkylated compound which is more labile. The final identification of 39 as 
an O6-alkylated adduct and 40 as an N2-alkylated adduct was based additionally on 
the lability of 39 under basic conditions, which was observed previously in the case 
of O-alkyl groups.89 Substance 38 was assigned as an N1-alkylated derivative based 
on its fragment ion 373 and the missing fragment ion 222. The N3-alkylated adduct 
was detected neither in PAM-dGuo reaction nor in CLB-dGuo reaction and one may 
speculate that this might be due to the large size of PAM/CLB molecule that make 
difficult for such molecule to react with the sterically hindered N3 site of dGuo. 
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However, knowing that PAM/CLB reacts with the N3 position of dAdo (see section 
3.3.1.) and that dAdo has same large size as dGuo, probably additional factors beside 


















































40 where n=1 for PAM
n=3 for CLB
Chart 17. Structures of 5’-O- (37), N1- (38), O6- (39), and N2- (40) alkylated derivatives of 
reactions between dGuo and PAM/CLB.
 Results and Discussion 39
figure 9. MS spectra of 5’-O adduct (a), N1 adduct (b), O6 adduct (c), and N2 adduct (d).
Substances 41-45 (Chart 18) all showed the same molecular ion of 594 in the case 
of reaction of dGuo with PAM. Compound 41 was identified as a N7,N9-bis adduct. 
44 and 45 were tentatively assigned as the N7 adducts derived from the reactions 
of two different PAM dimers with N7 of guanine; the corresponding derivatives 
were not observed in the reaction of dGuo with CLB.  The formation of N7,N9-bis 
alkylated adduct was expected, since its presence had previously been reported.161 
Compounds 42 and 43 could not be identified on the basis of their MS data, but 
they might be the isomeric adducts of 44 and 45 or positively charged dialkylated 
guanine analogs of 41.







































where n=1 for PAM
n=3 for CLB
Chart 18. Structures of N7,N9-bis alkylated adduct (41), and esters of N7-alkylated guanine 
derivatives (44, 45) formed by reactions between dGuo and CLB, dGuo and PAM.
Thus, many adducts were detected. N7-alkylated derivative was the main adduct 
among them. Other alkylation sites observed in the reaction of CLB/PAM with dGuo 
were 5’-O, N1, O6, N2 and N9. 
3.3.3. Reactions of chlorambucil and phenylacetic acid mustard with 
2’-deoxycytidine and 2’-deoxy-5-methylcytidine
The HPLC trace of the reaction of 2’-deoxycytidine with chlorambucil after 24 
hours is presented in Figure 10 and the corresponding HPLC trace of the reaction 
of 5-methyl-2’-deoxycytidine with chlorambucil is shown in Figure 11. dCtd and 
dMeCtd, which differ from one to another only by a methyl group in C-5 position, 
exhibit quite similar alkylation sites in their reactions with CLB/PAM. The structures 
of these adducts can be seen in Chart 19. The reaction of CLB with dCtd and dMeCtd 
is taken as an example.
figure 10. HPLC trace of the reaction of 2.5 mM CLB with 16.1 mM dCtd in 0.2 M cacodylic 
acid buffer (50 % base) after 24 hours at 37   ̊C.
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Four of the detected adducts (46a, 47a, 49a and 53) gave the same molecular ion 
477, which referred to a monomeric adduct of dCtd. The alkylation on the cytosine 
base of 46a is proven by the presence of the fragment ion of 361, which shows 
the loss of the sugar moiety. Further, the 1H resonance of the methylene group 
linked to the pyrimidine moiety exhibits values (4.37 and 4.08 ppm) comparable to 
those cases where the alkylation had occurred at the endocyclic nitrogen.153 Hence, 








































































































Chart 19. Structures of the products of the reactions between dCtd and CLB (46a to 52a, 
53), and dMeCtd and CLB (46b to 52b).
Substance 47a was characterized by the MS data. The mass spectrum showed a 
strong fragment ion 250, which indicated that the alkylation had occurred on the 
exocyclic oxygen150 (see 3.3.2.). 47a additionally had the fragment ions 361 and 366, 
which referred to the loss of alkylated cytosine base and alkylated sugar moiety, 
respectively. This could be explained by alkylation of O2 and migration of the alkyl 
group from O2 to 5’-O of the deoxyribose moiety in the spectrometer during the MS 
analysis. The corresponding O2-derivative was not observed in the reaction of PAM 
with dCtd.
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Substance 49a was characterized on the basis of the MS data that showed a fragment 
ion 366, referring to the loss of unmodified cytosine base. 49a was an adduct in 
which the alkylation had occurred at deoxyriboside moiety. 
Substance 53 was present in a very small amount. A tentative assignment was made 
on the basis of the molecular ion of 477 and a fragment ion of 361. In other words, a 
strong covalent bond between the alkyl moiety and the cytosine base did not brake 
further during ionization. This tentative assignment was further confirmed by the 
fast elution of 53 from the reverse-phase column which is specific to nucleosides 
with no alkylation on their heteroatoms. Even more, this type of adduct was not 
observed in the case of dMeCtd and Thd reaction with CLB, where C5 position is 
occupied by a methyl group. Thus, compound 53 was assigned as C5 adduct. The 
corresponding derivative was not detected in the reaction mixtures of PAM and 
pyrimidine nucleosides. While the reactions of C5-C6 double bond of pyrimidine 
nucleosides are well known, 162 the reactions of a carbon electrophile of an alkylating 
agent with C5 has not been mentioned before, to the best of our knowledge.
The structural assignment of 47a and 48a was based on the MS data and on the 
fact that 47a in acidic and neutral solutions gives rise to 48a as a major product, 
due to the destabilization of the N-glycosidic bond, 89, 163 and to diol 23 as a minor 
product. By contrast, under basic conditions, only the O2-alkyl group is cleaved 
from 47a (Scheme 7). This verifies that 47a is O2-alkylated deoxycytidine and 48a 
is O2-alkylated cytosine. The O2-alkyl pyrimidines are difficult to assign because 
of their instability.62 However, the identity of 48a was further proven by 1H NMR 
spectroscopy of the corresponding deglycosylated O2 adduct formed in the reaction 































scheme 7. General scheme showing the behavior of O2-alkyl deoxycytidine in neutral, acidic 
and basic conditions. 
Compound 50a showed a molecular ion of 478, which is typical for a deaminated 
adduct where N3 of the base moiety has been alkylated. This assignment was also 
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supported by the coelution of 50a with the product raised from the treatment of 
pure 46a with basic solution.
Based on their molecular ion of 726 and lability under basic conditions, substances 
51a and 52a were tentatively assigned as esters formed from the reaction of CLB 
dimer with N3 of dCtd. 
The HPLC trace of the reaction of chlorambucil with 5-methyl-2’-deoxycytidine 
is shown in Figure 11. The products formed in this reaction are similar to those 
obtained by the reaction of CLB with dCtd (Chart 19). 
figure 11. HPLC trace of the reaction of 2.5 mM CLB with 16.1 mM dMeCtd  in 0.2 M 
cacodylic acid buffer (50 % base) after 24 hours at 37  ̊C.
The major product was the N3 adduct 46b, as judged by 1H NMR and MS analyses. 
The carbohydrate derivative 49b, the deaminated N3 adduct 50b, and the N3 esters 
51b and 52b were present in comparable quantities in the reaction mixtures. The O2 
adducts, including O2-alkylated nucleoside and the corresponding nucleobase, were 
present in higher amount than in the reaction with dCtd: the relative abundance of 
(47b+48b) was 7.5 % compared to the relative abundance of (47a+48a) that was 
2.4 %; no explanation could be given for this difference.
The relative abundance of the O2-alkylated products in the reaction of dMeCtd with 
PAM was also much higher than in the case of dCtd: 8.3 % vs. 2.6 %. The deaminated 
derivative, in turn, was present in a very small amount. It even was very difficult to 
be detected.
No cross-linked derivative where a single CLB or PAM molecule was connected 
to two dCtd or two dMeCtd molecules could be detected. No alkylation at N4 of 
pyrimidine nucleosides was observed. In this respect the results differ from those 
of the earlier studies of cytidine with ethylating agents10 or 2’-deoxycytidine with 
epoxides,164 in which the N4-alkylated adduct was formed at neutral pH. 
The N3-alkylated dCtd and dMeCtd were relatively stable under the reaction 
conditions employed. Even so, they deaminated considerably to their corresponding 
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derivatives 50a and 50b at neutral pH, especially in the case of CLB. This was 
surprising because the spontaneous deamination of cytosine nucleoside is known 
to be slow. 162,165 Possibly the N3-alkylation enhances the deamination since the 
rates of deamination were similar for the N3 derivatives in the reactions of dCtd 
and dMeCtd with CLB; in this situation, the corresponding N3 derivative of dCtd-
PAM deaminated more readily than the corresponding dMeCtd-PAM. This is also 
unexpected because it is known that dMeCtd is more susceptible to deamination 
than dCtd.162 
N3 derivatives of dCtd and dMeCtd were treated in aqueous base and only the 
deaminated products were observed, in contrast to other cytosine derivatives166 
which gave also products of Dimroth rearrangement. 
Compound 54 is probably a nonnucleosidic impurity, as suggested by its UV and 
MS spectrum.
3.3.4. Reactions of chlorambucil and phenylacetic acid mustard with 
thymidine
Thymidine is the least reactive nucleoside among the purine and pyrimidine 
nucleosides studied in this thesis work. The HPLC trace of the reaction of 
chlorambucil with thymidine is shown in Figure 12 and the products formed in this 
reaction can be seen in Chart 20. 
figure 12. HPLC trace of the reaction of 2.5 mM CLB with 16.1 mM Thd in 0.2 M cacodylic 
acid buffer (50 % base) after 24 hours at 37  ̊C.























where n=1 for PAM
n=3 for CLB
Chart 20. Structures of products of thymidine – chlorambucil reaction
Product 50b was characterized by means of 1H NMR, MS/MS, HPLC-MS analyses 
and by coelution with the deaminated N3 derivative of 5-methyl-2’-deoxycytidine. 
50b is the N3 alkylated derivative and it is the main alkylation site of thymidine, as 
expected.167
The second abundant adduct, 55, was assigned as a carbohydrate derivative on 
the basis of the HPLC-MS analysis. No other adducts were detected in the case of 
thymidine. 
3.4.	 Reactions	of	chlorambucil	with	calf	thymus	DNA	
The reactions of CLB with single-stranded and double-stranded calf thymus DNA 
were performed in 0.2 M cacodylic acid (50 % base) at pH 6.8, at 37  ̊C for 24 hours. 
Then, the DNA was enzymatically hydrolyzed to 2’-deoxynucleosides. On the basis of 
NMR, UV, HPLC, LC-ESI-MS/MS studies, as well as by spiking with standard samples 
obtained in our previous work (i, ii), the major DNA-CLB adducts were assigned 
as N1 adduct of 2’-deoxyadenosine (28), N3 adduct of 2’-deoxyadenosine (29), N3 
adduct of 2’-deoxycytidine (46a) and N7 base adduct of 2’-deoxyguanosine (56) 
(Figure 13, Chart 21).  
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figure 13. HPLC trace of the reaction of chlorambucil (2.5 mM) with calf thymus single-
stranded DNA in 0.2 M cacodylic acid buffer (50 % base) after 24 hours at 37  ̊C.
Several minor products were detected and characterized by coelution with authentic 
samples and by MS. Among these adducts were N6 adduct of 2’-deoxyadenosine (32), 
N7-alkylated nucleoside (58) and N7,N7-bis (57) adducts of  2’-deoxyguanosine, 
deaminated N3 (50a) and O2-alkylated (47a) adducts of 2’-deoxycytidine, and N3 
adduct of thymidine (50b). All these products were present in the hydrolysates 
of both, single-stranded and double-stranded DNA. 57 was the only crosslink 
detected. 
Other adducts (60, 31, 49a) were tentatively characterized as “sugar” derivatives 
based on their MS data. They might be 3’-O-alkylated nucleoside, knowing that the 
5’-O of DNA is phosphorylated. On other hand, the DNA does not have many free 
3’-hydroxy groups and these products may be artifacts. 





























































































Base = Gua; 60
Base = Ade; 31








































where Ar = (CH2)3COOH
OH
Chart 21. Structures of products of reactions of CLB with ssDNA and dsDNA
N7,N9-Bis alkylated derivative of guanine (41) was also observed, as well as other 
minor adducts. 
These reactions were performed in non-nucleophilic buffer, which means that a 
CLB molecule has only two options: to react with water (hydrolyses) or to react 
with DNA. Important to remember is also that the reactivity and concentration of 
nucleophile determines the site of reaction. 
Single-stranded DNA was approximately 3.4 times more reactive than double-
stranded DNA. The reactivity order in ssDNA and dsDNA was partially different 
than in the case of nucleobases (Table 2). The most reactive site in ssDNA was N1 
of Ade, then N7 of Gua, N3 of Cyt and N3 of Ade. The order of reactivity, from most 
reactive site to less reactive site, in dsDNA was: N3 of Ade, N7 of Gua, N3 of Cyt  and 
N1 of Ade, last two being approximately equally reactive. 
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Table 2. The order of reactivity of the nucleophilic sites of nucleobases with CLB.
more reactive                    less reactive
Nucleosides Gua-N7 Ade-N1 Cyt-N3 Ade-N7 / Ade-N3
ssDNA Ade-N1 Gua-N7 Cyt-N3 Ade-N3
dsDNA Ade-N3 Gua-N7 Cyt-N3 / Ade-N1 Cyt-N3 / Ade-N1
Surprising was that N3 of Ade was the most reactive site in dsDNA, and not N7 of 
Gua. It is known from different studies on the reaction of chlorambucil with DNA 
that the principal site of alkylation is N7 of guanine168,169,170 and the second site is 
N3 of adenine.171 The reason for this situation is that guanine N7 is situated in the 
major groove and easily accessible for different alkylating agents, while adenine N3 
is accommodated with very little distortion of the DNA helix.172
Also surprising was that N1 of Ade was the most reactive site in ssDNA, and N7-
alkylated adduct of Ade could not be detected in ssDNA or in dsDNA.
It is known that the nucleophilic sites of nucleobases participating to the base 
pairing in dsDNA are partly protected from alkylation. That could be observed also 
in our case, where the N3 of Cyt and N1 of Ade were less reactive in dsDNA than in 
ssDNA. Exception is offered by the O2-alkylated adduct of dCtd which was stable 
enough to be found also in the hydrolysate of dsDNA.
The molar yields of the main adducts were calculated from the original amount of 
2-deoxyribonucleosides (Table 3).
Table 3. Yields of the major adducts present in the DNA hydrolysate.
Adducts mol/106 mol of 
normal nucleotides gua-N7 dAdo-N1 Ade-N3 dCtd-N3
ssDNA 320 390 224 234
dsDNA 90 3 245 4
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4. suMMARy AND CONClusiONs
CLB (8) was found to be hydrolytically slightly less stable than its metabolite PAM (21). 
CLB and PAM reacted with different heteroatoms of the 2’-deoxyribonucleosides, 
even though the predominant reaction observed was the hydrolysis of 8 and 21. 
The overall reactivity of CLB towards dGuo,150  dAdo, dCtd, dMeCtd, and Thd was 
approximately 24, 7, 10, 10, and < 1 %, respectively, based on the decrease of the 
products of CLB hydrolysis. PAM’s overall reactivity towards dGuo, dAdo, dCtd, 
dMeCtd, and Thd was ca. 25, 10, 10, 10, and < 1 %, respectively, based on the decrease 
of the products of PAM hydrolysis. One difference in the reactivity of CLB and PAM 
is that the N3 dCtd-PAM adduct was deaminated easier than the corresponding CLB 
derivative.
The order of reactivity of the nucleophilic sites of nucleobases with chlorambucil is 
in accordance with previous data,173 while the situation was different in the case of 
ssDNA and dsDNA: nucleosides  Gua-N7 > Ade-N1 > Cyt-N3 > Ade-N7 = Ade-N3, 
ssDNA  Ade-N1 > Gua-N7 > Cyt-N3 > Ade-N3, and dsDNA   Ade-N3 > Gua-N7 
> Cyt-N3 = Ade-N1.
This thesis work was concentrated at first on the analyses of the nucleosides’ 
reactions with CLB and PAM and the data obtained from them was used as example 
for the reactions of DNA with CLB. Many adducts were detected and characterized in 
our work and they may be of biological importance. The medical implication of DNA 
damage caused by alkylation is becoming more and more important.13 For example, 
in the clinical chemotherapy, identifying the CLB adducts formed with DNA, as well 
as the system used in their repair, help in understanding the drug resistance and its 
side effects.174 CLB and PAM have similar chemical behavior, as we have showed,121 
and this is in accordance with the previous suggestions that these two mustards 
cause DNA lesions with similar effectivines.80,175 
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5. exPeRiMeNTAl seCTiON
5.1. General
2’-Deoxyribonucleosides (dGuo, dAdo, dCtd, dMeCtd, and Thd), cacodylic acid, 
N,N-bis(2-chloroethyl)-p-aminophenylbutyric acid, calf thymus DNA (Type I: 
sodium salt, highly polymerized), nuclease P1 from Penicillium citrinum, alkaline 
phosphatase (Escherichia coli Type III), acid phosphatase (wheat germ Type I) 
and bis[2-hydroxyethyl]iminotris[hydroxymethyl]methane hydrochloride (Bis-
tris) buffer were purchased from Sigma, and they were used as received. N,N-
Bis(2-hydroxyethyl)-p-aminophenylbutyric acid and {4-[bis(2-chloroethyl)amino]
phenyl}acetic acid were synthesized as described previously.130,140 All inorganic 
reagents were of ACS grade or better.
5.2.	 Chromatographic	methods
Analytical	HPLC analyses were performed on a Hewlett-Packard 1090 Instrument 
equipped with a diode array detector and autosampler. The reversed-phase column 
in use was Hypersil ODS2 C18, 4.6 mm × 250 mm with particle size of 5 µm (i), 
or Waters Symmetry C18, 4.6 mm × 150 mm with particle size of 3.5 µm (ii, iii, 
iv). The columns were eluted with different gradients of acetonitrile in 10 mM 
ammonium acetate containing 0.1 % of acetic acid, and with a flow rate of 1 mL 
min-1. The solvents for chromatography were filtered and degassed prior use. The 
reaction mixtures were injected directly to the HPLC.
Preparative	 HPLC analyses (isolation of adducts) were performed on a Merck-
Hitachi instrument consisting of a L-6200A Intelligent pump, L-4000 UV detector, 
and D-2500 Chromato-Integrator. Hypersil C18 reversed-phase column with 
dimensions of 10 mm × 250 mm, and particle size of 8 µm (i, ii), or  Hypersil ODS 
C18 column, 10 × 250 mm, and particle size of 5 µm (iii), or Waters SymmetryPrep 
C18 with diamentions of 7.8 mm × 150 mm and particle size of 7 µm (iii, iv) were 
used for these analyzes. Same buffers as in analytical HPLC were used. The flow 
rate of the eluents (buffers) was 4 mL min-1 (i, ii), or 2 mL min-1 (iii, iv), or 2.5 mL 
min-1 (iv).
5.3.	 Spectroscopic	and	spectrometric	methods
All adducts were characterized by nuclear magnetic resonance spectroscopy, 
ultraviolet spectroscopy and mass spectrometry. 
NMR	analyses were performed on JEOL Alpha 500 instrument operating at 500.0 
MHz for 1H (i), Bruker Avance 600 spectrometer (ii, iii) and Bruker Avance 500 
spectrometer (iv) equipped with BBO-5mm-Zgrad probe operating at 500.13 and 
125.77 MHz for 1H and 13C, respectively. Isolated pure compounds were dissolved 
in D2O and the signal of HDO was used as an internal reference in i, ii, iii. DMSO-d6 
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was used as a solvent for the NMR samples in iv and its instrument’s value was 
used as an internal reference.
Depending on the amount of isolated product and of how much information was 
required from that specific sample, different NMR experiments were performed: 1H 
NMR, 13C NMR, COSY, NOESY, HSQC, HMBC.
The HPLC instrument was equipped with a diode-array detector that recorded the 
UV	spectra of adducts as the compounds eluted from the reversed-phase liquid 
chromatography column. 
The MS	analyses were performed on several mass-spectrometry instruments: a 
Perkin-Elmer Sciex API-365 Triple-Quadrupole LC/MS/MS system, equipped with 
a PE 200 Micro pump and a PE Series 200 Autosampler (i); a Perkin-Elmer Sciex 
API-365 Triple-Quadrupole LC/MS/MS system, equipped with two PE 200 Micro 
pumps, a PE Series 200 Autosampler, and an Applied Biosystems 783A UV detector 
connected to a LKB 2210 two channel recorder (ii); an Applied Biosystems API-4000 
Triple-Quadrupole LC/MS/MS system, equipped with a Shimadzu-Prominence HPLC 
system and an Applied-Biosystems-783A UV detector connected to an LKB-2210 
two-channel recorder (iii); an Agilent 1100 Series LS/MSD Trap SL instrument, 
equipped with an electrospray source (iv); and Micro LC triple-quadrupole mass 
spectrometer, equipped with an electrospray interface (iv).
Same RP-HPLC columns and buffers used in the analytical HPLC analyses were used 
also in the MS analyses. 
A variety of mass-spectrometry studies were done in order to obtain a consistent 
characterization of products: HPLC/MS, MS/MS, HPLC/ESI-MS, HPLC/ESI-MS/MS.
5.4.	 Quantitative	product	analyses
Overall	 reactivity	 of	 chlorambucil	 and	 phenylacetic	 acid	 mustard	 with	
nucleosides. CLB was allowed to react in the presence and absence of 
2’-deoxyribonucleosides over night in cacodylic acid buffer at 37  ̊C. The reaction 
mixtures were analyzed by analytical HPLC and the amount of nonnucleosidic 
products 23-27 was quantitated by HPLC at 267 nm (isosbestic point of the 
reaction of CLB and PAM with nonchromophoric nucleophiles139) in the absence of 
nucleosides. Then the amount of 2’-deoxyribonucleosides alkylation was calculated 
based on the decrease of the mole fraction of 23-27 in the presence of nucleosides. 
Similar procedure was used in the case of PAM too.
CLB and PAM were also allowed to react in the presence and absence of 1H-imidazole 
in cacodylic acid buffer (50 % base, 1.0 M NaClO4, pH 7.4), in the presence of 
2’-deoxyribonucleosides. The mole fraction of all products (CLB and PAM with 
imidazole, CLB and PAM with nucleosides) were calculated as described above.
Relative adduct levels. The relative levels of the most-relevant adducts formed 
by reaction of CLB or PAM with nucleosides were calculated considering that all 
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adducts of each nucleoside have same extinction coefficient. Reaction mixtures 
were run on analytical HPLC and the yield of the most abundant adduct of each 
nucleoside was considered as 100 %; other adducts were calculated by comparison 
with it.  
Determination	of	adducts’	yields	with	calf	thymus	DNA. The yields of the major 
adducts of CLB reaction with ssDNA and dsDNA where determined based on the 
quantitative 1H NMR analysis.176,177,178 
Dry isolated adducts were dissolved in a known amount of D2O in the case of CLB-
dAdo and CLB-dCtd, and in DMSO-d6 in the case of CLB-dGuo. A known amount of a 
5 % triethylamine solution in D2O and DMSO-d6, respectively was added to each of 
the adduct sample as an internal standard and 1H NMR was run. The concentration 
of adduct in each NMR sample was calculated by comparing the integral of one 
proton signal of adduct to the integral of the CH3 signal of triethylamine, of which 
concentration was known. An exact volume of NMR sample was diluted with a 
suitable volume of water and run on a HPLC instrument equipped with a diode array 
detector. The UV detection used was at 267 nm and the quantitative determination 
of adducts was done by comparing the peak area of these HPLC standard samples 
with the peak area of adducts in the reaction mixtures. The original amount of 
2’-deoxyribonucleosides in the reaction mixture was used to calculate the molar 
yields of adducts. 
5.5.	 Stability	of	the	end	products
CLB and PAM were allowed to react with nucleosides in 0.2 M cacodylic acid buffer, 
37 ̊C for 24 hours. The products were isolated by preparative HPLC. The collected 
fractions were concentrated and then dissolved in 0.1 M NaOH, 0.1 M HCl, or 0.2 
M cacodylic acid (50 % base); after 24 hours at 37 ̊C, samples were analyzed by 
HPLC.
5.6.	 Dimroth	rearrangement
CLB and PAM were allowed to react with 2’-deoxyadenosine overnight in the 0.2 
M cacodylic acid buffer (50 % base, pH 6.8) at 37  ̊C. The N1 adduct was separated 
by semipreparative HPLC from the reaction mixture, diluted 10-fold with cacodylic 
acid buffer or 0.1 M NaOH and kept overnight at 37  ̊C (i) or room temperature (iii). 
HPLC was used to follow the reactions. The mixture was neutralized with aqueous 
HCl prior HPLC analysis. 
5.7.	 Kinetic	measurement	
Reactions were carried out in a nonnucleophilic buffer (0.2 M cacodylic acid buffer, 
50 % base, pH 6.8) at 37  ̊C for 24 hours in the presence and absence of dAdo, 
dGuo, dCtd, dMeCtd, and Thd (16.1 mM). The initiation of the reactions was done by 
adding a stock solution of CLB or PAM in acetonitrile so that a final concentration of 
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0.6 mM CLB (i) or 2.5 mM CLB (iii) and 2.5 mM PAM (iii) was obtained. The final 
reaction mixtures included 1 % (v/v) acetonitrile. 
In the case of PAM, the ionic strength of the cacodylic acid buffer was adjusted to 
1.0 M with NaClO4.
Reactions were performed in stoppered bottles and aliquots withdrawn at suitable 
intervals from the reaction mixture were cooled down in ice-water bath, then stored 
at -20  ̊C and melted before the high-performance liquid chromatography analysis. 




Chlorambucil (0.6 mM in i, 2.5 mM in ii) and phenylacetic acid mustard (2.5 mM 
in iii) were allowed to react overnight in a nonnucleophilic buffer (aqueous 0.2 
M cacodylic acid, 50 % base, pH 7.4) at 37 °C in the presence of dGuo, dAdo, dCtd, 
dMeCtd, and Thd (16.1 mM), respectively. The reaction mixtures were analyzed 
by HPLC techniques after 24 hours and main adducts formed were isolated by 
preparative HPLC, then characterized and identified based on their UV spectra, 
HPLC/MS, HPLC/ESI/MS, HPLC/MS/MS data and/or 1H NMR spectra. 
5.9.	 Reactions	of	chlorambucil	with	calf	thymus	DNA	
The reactions of CLB with calf thymus DNA were performed in similar conditions 
to the reactions of CLB with nucleosides, with one exception: concentration of DNA 
was different than the concentration of nucleosides.
Single-stranded (ss) DNA was obtained from double-stranded (ds) DNA by heating 
the solution of dsDNA to 100 °C for 10 min and then cooling it down rapidly on 
ice.179 Chlorambucil was allowed to react with ssDNA and dsDNA, respectively in 
0.2 M cacodylic acid buffer (50 % base) overnight at physiological pH and 37 °C. 
The modified DNA was enzymatically hydrolyzed to 2’-deoxyribonucleosides by 
following the methods described in the literature.178 The precipitation of DNA was 
done by adding 5 M NaCl solution, cold ethanol and cooling the DNA solution to -20 
̊C. The mixtures were centrifuged and the recovered DNA was washed with cold 70 % 
ethanol, cold ethanol and then dissolved in water. The DNA was reprecipitated from 
the solution adding cold ethanol, cooling to -20  ̊C and recovered by centrifugation. 
The recovered DNA was enzymatically hydrolyzed by dissolving it in 100 mM Bis-
tris-MgCl2 buffer, adding Nuclease P1, bacterial alkaline phophatase, wheat germ 
acid phosphatase and incubating for several hours at 37  ̊C. The enzymatically 
digested mixtures were filtered while centrifuging, then the ultrafiltrates were 
collected, evaporated to dryness, reconstituted in 20 % methanol solution and 
analyzed by HPLC and LC-ESI-MS/MS. 
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